FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The company’s Growth Portfolio delivered $6.2 billion in revenue
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
